Objectives Although prenatal ultrasound is broadly used to detect abnormal
fetuses, the variability in the interpretation of second-trimester prenatal
ultrasound examinations is unknown. We sought to evaluate the consistency
of the interpretation of prenatal ultrasound Examinations.
Design Physicians who perform prenatal ultrasound and who participate in th
e California Maternal Serum Expanded AFP program were asked to interpret se
ries of rest ultrasound examinations. The series of cases Er,as selected to
include a random sample of fetal structural abnormalities, ultrasound mark
ers that have been associated with chromosomal abnormalities. and normal ca
ses. Interobserver agreement was evaluated using a kappa statistic for each
organ system. The sensitivity and false-positive rate were calculated for
detecting specific anatomic abnormalities within each organ system.
Results Of the 210 sonologists eligible for inclusion in the study, complet
ed responses were received from 148 (70%). There was moderate to substantia
l agreement between physicians in reporting the presence of fetal abnormali
ties for all organ systems (kappa range 0.40-0.88, P < 0.001). The consiste
ncy was highest for the central nervous system (CNS), neck. and face. Withi
n each organ system, the consistency was similar for major structural abnor
malities and ultrasound markers of chromosomal abnormalities. The sensitivi
ty ranged from 62% (95% confidence interval (CI) 58-66%) for major renal ab
normalities to 91% (95% CI 88-94%) for CNS abnormalities, with correspondin
g false-positive rates of 7% (95% CI 6-9%) for renal abnormalities and 9% (
95% CI 7-11%) for CNS abnormalities. For most organ systems, the sensitivit
y for detecting ultrasound markers of chromosomal abnormalities was similar
to the sensitivity for detecting structural abnormalities.
Conclusion There is moderate to substantial agreement in the interpretation
of second-trimester prenatal ultrasound examinations. Whether the identifi
cation of specific ultrasound abnormalities and markers is overall benefici
al to patients remains to be determined.